Alberto Zambon

List of Publications by Year
in descending order

28 papers	2,545 citations	516710 16 h-index	552781 26 g-index
28 all docs	28 docs citations	28 times ranked	3973 citing authors

#	Article	IF	Citations
1	Waist circumference as a vital sign in clinical practice: a Consensus Statement from the IAS and ICCR Working Group on Visceral Obesity. Nature Reviews Endocrinology, 2020, 16, 177-189.	9.6	790
2	Visceral and ectopic fat, atherosclerosis, and cardiometabolic disease: a position statement. Lancet Diabetes and Endocrinology,the, 2019, 7, 715-725.	11.4	687
3	SGLT2 Inhibitors and the Diabetic Kidney. Diabetes Care, 2016, 39, S165-S171.	8.6	279
4	The selective peroxisome proliferator-activated receptor alpha modulator (SPPARMÎ±) paradigm: conceptual framework and therapeutic potential. Cardiovascular Diabetology, 2019, 18, 71.	6.8	104
5	Hepatic lipase: a marker for cardiovascular disease risk and response to therapy. Current Opinion in Lipidology, 2003, 14, 179-189.	2.7	88
6	Practical guidance for combination lipid-modifying therapy in high- and very-high-risk patients: A statement from a European Atherosclerosis Society Task Force. Atherosclerosis, 2021, 325, 99-109.	0.8	83
7	Current practice in identifying and treating cardiovascular risk, with a focus on residual risk associated with atherogenic dyslipidaemia. European Heart Journal Supplements, 2016, 18, C2-C12.	0.1	71
8	Compositional Differences of LDL Particles in Normal Subjects With LDL Subclass Phenotype A and LDL Subclass Phenotype B. Arteriosclerosis, Thrombosis, and Vascular Biology, 1996, 16, 1040-1046.	2.4	71
9	A review of the evidence on reducing macrovascular risk in patients with atherogenic dyslipidaemia: A report from an expert consensus meeting on the role of fenofibrateâ€“statin combination therapy. Atherosclerosis Supplements, 2015, 19, 1-12.	1.2	66
10	Relevance of hepatic lipase to the metabolism of triacylglycerol-rich lipoproteins. Biochemical Society Transactions, 2003, 31, 1070-1074.	3.4	62
11	Review article: the metabolic syndrome - a chronic cardiovascular inflammatory condition. Alimentary Pharmacology and Therapeutics, 2005, 22, 20-23.	3.7	48
12	Red Yeast Rice for Hypercholesterolemia. Journal of the American College of Cardiology, 2021, 77, 620-628.	2.8	41
13	Omega-3 polyunsaturated fatty acids supplementation and cardiovascular outcomes: do formulation, dosage, and baseline cardiovascular risk matter? An updated meta-analysis of randomized controlled trials. Pharmacological Research, 2020, 160, 105060.	7.1	30
14	Lipoprotein remnants and dense LDL are associated with features of unstable carotid plaque: A flag for non-HDL-C. Atherosclerosis, 2013, 230, 106-109.	0.8	26
15	Effects of Niacin Combination Therapy With Statin or Bile Acid Resin on Lipoproteins and Cardiovascular Disease. American Journal of Cardiology, 2014, 113, 1494-1498.	1.6	24
16	Reported muscle symptoms during statin treatment amongst Italian dyslipidaemic patients in the realâ€life setting: the PROSISA Study. Journal of Internal Medicine, 2021, 290, 116-128.	6.0	21
17	Omega n-3 Supplementation: Exploring the Cardiovascular Benefits Beyond Lipoprotein Reduction. Current Atherosclerosis Reports, 2020, 22, 74.	4.8	9
18	Fenofibrate increases circulating haematopoietic stem cells in people with diabetic retinopathy: a randomised, placebo-controlled trial. Diabetologia, 2021, 64, 2334-2344.	6.3	9

#	Article	IF	Citations
19	Common hepatic lipase gene promoter variant predicts the degree of neointima formation after carotid endarterectomy: Impact of plaque composition and lipoprotein phenotype. Atherosclerosis, 2006, 185, 121-126.	0.8	7
20	Residual cardiovascular risk in secondary prevention. Internal and Emergency Medicine, 2011, 6, 61-68.	2.0	6
21	The burden of cholesterol accumulation through the lifespan: why pharmacological intervention should start earlier to go further?. European Heart Journal - Cardiovascular Pharmacotherapy, 2021, 7, 435-441.	3.0	6
22	Hypercholesterolemia and cardiovascular disease: Focus on high cardiovascular risk patients. Atherosclerosis Supplements, 2020, 42, e30-e34.	1.2	6
23	Non- high-density lipoprotein cholesterol and cardiovascular disease in patients with diabetic dyslipidaemia. Diabetes Mellitus, 2020, 23, 65-71.	1.9	6
24	Progress and prospects of biological approaches targeting PCSK9 for cholesterol-lowering, from molecular mechanism to clinical efficacy. Expert Opinion on Biological Therapy, 2020, 20, 1477-1489.	3.1	2
25	Lipid Profile and Vascular Remodelling in Young Dyslipidemic Subjects Treated with Nutraceuticals Derived from Red Yeast Rice. Cardiovascular Therapeutics, 2021, 2021, 1-8.	2.5	2
26	The new ACC/AHA guidelines on the treatment of dyslipidemia: cons. Internal and Emergency Medicine, 2015, 10, 119-122.	2.0	1
27	The Multicentre Atorvastatin Plaque Stabilisation (MAPS) Study. High Blood Pressure and Cardiovascular Prevention, 2003, 10, 11-18.	2.2	0
28	The Association of Proprotein Convertase Subtilisin/Kexin Type 9 to Plasma Low-Density Lipoproteins: An Evaluation of Different Methods. Metabolites, 2021, 11, 861.	2.9	0